

Statement Pursuant to the Pink Basic Disclosure Guidelines

ONCOLOGY PHARMA, INC.

A Nevada Corporation
One Sansome Street
Ste. 305 PMB # 100517
San Francisco CA 94104

(415) 869 1038

info@oncology-pharma.com

2834

Quarterly Report
For the Period Ending June 30, 2020:
(the "Reporting Period")

As of The Current Reporting Period (Quarter ended June 30,2020), the number of shares outstanding of our Common Stock was:

150,146,092

As of June 30, 2019, the number of shares outstanding of our Common Stock was:

124,896,092

As of August 11,2020, the number of shares outstanding of our Common Stock was: 155,146,092

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:X

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No: X

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period: Yes:

NoX

1) Name of the issuer and its predecessors (if any)

Oncology Pharma, Inc. Nevada, Active
SourcingLink.net, Inc.
Nevada until 4-19
QCS Corp. until 7-99
Parkway Capital Corp until 6-94

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:X

Trading symbol: ONPH

Exact title and class of securities outstanding: common

CUSIP: 836171 20 7

Par or stated value: \$0.001

Total shares authorized: 900,000,000 as of date: August 11, 2020

Total shares outstanding: 155,146,092 as of date: August 11, 2020

Number of shares in the Public Float: 19,927,822 as of date: August 11, 2020

Total number of shareholders of record: 201 as of date: August 11, 2020

Additional class of securities (if any):

Trading symbol: n/a

Exact title and class of securities outstanding: preferred

CUSIP: n/a

Par or stated value: \$0.001

Total shares authorized: 100,000,000 as of date: August 11, 2020

Total shares outstanding: 1 as of date: August 11, 2020

Transfer Agent

Olde Monmouth Stock Transfer Co. Inc.

200 Memorial Pkwy

Atlantic Highlands, NJ, 07716

(732)872-2727

matt@oldemonmouth.com

Is the Transfer Agent registered under the Exchange Act? Yes:X No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

none

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None

A. Changes to the Number of Outstanding Shares

There were no changes to the number of outstanding common shares during the quarter ended June 30, 2020 as compared to the Fiscal Year ended March 31, 2020.

Issuances past two completed fiscal years and any subsequent interim period:

Number of Shares outstanding as of
April 1, 2018

Opening Balance:
Common: 116,412,469
Preferred: 1,000

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
12/14/2018	new	4,000,000	common	\$0.01	No	Tulynode BioSciences, Inc (Control Person Philip Kim)	Licencing agreement	restricted	4(a)(2)
12/14/2018	new	100,000	common	\$0.01	No	Philip Kim	consulting	restricted	4(a)(2)
12/14/2018	new	1,000,000	common	\$0.01	No	Vjay Mahant	consulting	restricted	4(a)(2)
12/14/2018	new	100,000	common	\$0.01	no	Vjay Mahant	consulting	restricted	4(a)(2)
2/26/2019	New	10,250,000	common	\$0.01	No	Carlos Barnett	Consulting	restricted	4(a)(2)
2/26/19	New	10,250,000	common	\$0.01	No	Shawn Crouse	Consulting	restricted	4(a)(2)
2/26/2019	New	35,000,000	common	\$0.01	No	Charles Wagner	Consulting	restricted	4(a)(2)
2/26/2019	New	5,000,000	common	\$0.01	No	Vjay Mahant	Cash	Restricted	4(a)(2)
3/27/2019	New	100,000	common	\$0.02	no	Dr. Argyrios Theofilopoulos	Consulting	Restricted	4(a)(2)
3/27/2019	New	750,000	Common	\$0.02	No	NanoSmart Pharmaceuticals, Inc (Control Person Henry Smith)	Licencing agreement	Restricted	4(a)(2)

Number of Shares outstanding as of
April 1, 2019

:
Common: 124,896,092
Preferred: 1,000

7/16/2019	new	100,000	common	\$0.01	n.a	Dr. Stefan Gruenwald	consulting	restricted	4(a)(2)
8/26/2019	new	2,500,000	common	\$0.05	No	Kalos Therapeutics (Control Person Henry Smith)	licensing	restricted	4(a)(2)
9/17/2019	new	8,500,000	common	0.0297	No	Dr. Stefan Gruenwald	consulting	restricted	4(a)(2)
10/30/2019	new	1,500,000	common	\$0.03	no	George Malasek	consulting	restricted	4(a)(2)
10/30/2019	New	100,000	common	\$0.03	No	Daniel Chasse	Consulting	restricted	4(a)(2)
10/30/2019	new	500,000	common	\$0.03	no	Dimitrios Theofilopoulos	consulting	restricted	4(a)(2)
11/12/2019	New	300,000	common	\$0.03	No	Dimitrios Theofilopoulos	Consulting	restricted	4(a)(2)
12/19/2019	New	12,500,000	common	\$0.03	No	Bright Star International, Inc. (Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144

2/26/2020	New	250,000	common	\$0.02	No	NanoSmart Pharmaceuticals, Inc (Control Person Henry Smith)	License Fee	restricted	4(a)(2)
-----------	-----	---------	--------	--------	----	---	-------------	------------	---------

Shares Outstanding on
March 31,2020

Ending Balance:
Common: 150,146,092
Preferred: 1,000

						(subsequent issuances)					
8/11/2020	new	5,000,000	common	0.0085	No	Kalos Therapeutics (Control Person Henry Smith)	licensing	restricted	4(a)(2)		

B. Debt Securities, Including Promissory and Convertible Notes

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount At issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms	Holder	Control Person	Reason
4/4/14	5550	8500	0	4/4/2015	0.0001	Bright Star International	Kevin Dills	Working Capital
11/25/16	2000	2000	0	11/25/2017	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/20/17	2700	2700	0	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/3/17	3000	3000	0	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/12/17	1100	1100	0	4/12/2018	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
5/5/17	30000	30000	0	5/5/2018	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
5/9/17	12000	12000	0	5/9/2018	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
9/14/17	4000	4000	0	9/14/2018	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
10/30/17	3500	3500	0	10/30/2018	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/5/18	6000	6000	0	1/5/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/18/18	1000	1000	0	1/18/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/5/18	3000	3000	0	3/5/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/23/18	2500	2500	0	3/23/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/20/18	3500	3500	0	4/20/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
5/18/18	5500	5500	0	5/18/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
7/20/18	1500	1500	0	7/20/2019	0.0080	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
8/6/18	1100	1100	0	8/6/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
8/31/18	1400	1400	0	8/31/2019	0.0090	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
11/15/18	3250	3250	0	11/15/2019	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/1/19	3500	3500	0	1/1/2020	0.0007	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/15/19	1100	1100	0	1/15/2020	0.0007	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
1/23/19	4200	4200	0	1/23/2020	0.0050	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
2/8/19	1750	1750	0	2/8/2020	0.0007	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/1/19	2500	2500	0	On Demand	0.0050	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/6/19	3500	3500	0	On Demand	0.0050	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/6/19	3000	3000	0	4/5/2020	0.0007	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
6/25/19	1050	1050	0	6/24/2020	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
10/31/19	4300	4300	0	4/30/2020	0.0007	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
11/1/19	1300	1300	0	On Demand	0.0050	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
12/31/19	2100	2100	0	6/30/2020	0.0001	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/11/20	3500	3500	0	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
3/27/20	1600	1600	0	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/6/2020	600	600	13	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/15/2020	3750	3750	78	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
4/30/2020	2000	2000	36	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
5/21/2020	2000	2000	30	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
5/29/2020	1250	1250	17	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
6/30/2020	2300	2300	19	On Demand	0.0010	Charles Wagner	Charles Wagne	Working Capital
6/30/2020	5350	5350	44	On Demand	0.0010	Charles Wagner	Charles Wagne	Working Capital
7/20/2020	6000	6000	30	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
7/28/2020	5500	5500	20	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
7/28/2020	2500	2500	9	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital
8/6/2020	10000	10000	21	On Demand	0.0010	Life Sciences Journeys, Inc.	Karen Alanis	Working Capital

4) Financial Statements

A. The following financial statements were prepared in accordance with:

U.S. GAAP

B. The financial statements for this reporting period were prepared by:

Name: Charles Wagner

Title: Chairman

Relationship to Issuer: Chairman of the Board of Directors

Oncology Pharma, Inc.
(Formerly Sourcelink.Net)
BALANCE SHEETS
(unaudited)

	As of June 30, 2020	As of March 31, 2020
ASSETS		
CURRENT ASSETS		
Cash	\$ 36	\$ 1,805
Total Current Assets	<u>36</u>	<u>1,805</u>
INVESTMENTS		
Investment in Carbonite Claims	600	600
Investment in Lac Fire Property	114,694	114,694
Investment in Tulynode Biosciences Licensing Agreement	0	0
Investment in NanoSmart Pharmaceuticals, Inc. Licensing Agreement	16,650	16,650
Investment in Kalos Therapeutic Inc. Licensing Agreement	125,000	125,000
Total Investments	<u>256,944</u>	<u>256,944</u>
FIXED ASSETS	<u>502</u>	<u>779</u>
Total Fixed Assets	<u>502</u>	<u>779</u>
TOTAL ASSETS	<u>\$ 257,482</u>	<u>\$ 259,528</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts Payable and Accrued Expenses	165,204	\$ 165,109
Loans Payable Related Party	910	910
Notes Payable, Related Party	0	2,500
Convertible Notes Payable, Related Party	7,850	
Convertible Notes Payable	135,600	126,000
Total Current Liabilities	<u>309,564</u>	<u>294,519</u>
Total Liabilities	<u>\$ 309,564</u>	<u>\$ 294,519</u>
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock at \$0.001 par value : 100,000,000 shares authorized, 1 share issued and outstanding of 1,000 designated Series A	1,000	1,000
Common Stock (\$.001 par value) 900,000,000 shares authorized; 150,146,092 issued and outstanding as of March 31, 2020 and June 30,2020	150,146	150,146
Additional Paid in capital	69,784,384	69,784,384
Retained Deficit	(69,987,612)	(69,970,521)
Total Stockholders' Equity (Deficit)	<u>(52,082)</u>	<u>(34,991)</u>
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	<u>\$ 257,482</u>	<u>\$ 259,528</u>

The Accompanying Notes are an Integral Part of These Financial Statements

Oncology Pharma, Inc.

(Formerly Sourcelink.Net)

STATEMENT OF OPERATIONS

(unaudited)

	Three Months Ended June 30,2020	Three Months Ended June 30,2019
REVENUES	\$ -	\$ -
COSTS AND EXPENSES		
General and Administrative	16,719	14,736
Depreciation	277	222
Total Operating Expenses	16,996	14,958
Operating Loss	(16,996)	(14,958)
OTHER INCOME AND EXPENSES		
Interest Expense	(95)	0
Total Other Income and Expense	(95)	0
Net Loss Before Taxes	(17,091)	(14,958)
Income Taxes	0	0
Net Loss	\$ (17,091)	\$ (14,958)
Net Loss Per Common Share (Basic and Diluted)	\$ (0.00)	\$ (0.00)
Weighted Average Common Shares Outstanding (Basic and Diluted)	150146092	124896092

The Accompanying Notes are an Integral Part of These Financial Statements

Oncology Pharma, Inc.

(Formerly Sourcelink.Net)

STATEMENT OF SHAREHOLDER'S EQUITY (DEFICIT)

for the quarter ended June 30, 2019

(unaudited)

	Shares	Amount	Shares	Amount	Paid in Capital	Retained Deficit	Stock Be Issued	Total
Balance 40/1/2019	1,000	\$ 1,000	124,896,092	\$ 124,896	\$ 69,353,024	\$ (69,791,638)	\$100,000	\$(212,718)
Loss Three Months Ended June 30, 2019						(14,958)		(14,958)
Balance 6/30/2019	1,000	\$ 1,000	124,896,092	\$ 124,896	\$ 69,353,024	\$ (69,806,596)	\$100,000	\$(227,676)

Oncology Pharma, Inc.

(Formerly Sourcelink.Net)

STATEMENT OF SHAREHOLDER'S EQUITY (DEFICIT)

for the quarter ended June 30, 2020

(unaudited)

	Shares	Amount	Shares	Amount	Paid in Capital	Retained Deficit	Stock Be Issued	Total
Balance 4/31/2020	1,000	\$ 1,000	150,146,092	\$ 150,146	\$ 69,784,384	\$ (69,970,521)	0	\$(34,991)
Loss Three Months Ended June 30, 2020						(17,091)		(17,091)
Balance June 30, 2020	1,000	\$ 1,000	150,146,092	\$ 150,146	\$ 69,784,384	\$ (69,987,612)	0	\$(52,082)

The Accompanying Notes are an integral part of these Financial Statements

Oncology Pharma, Inc.
(Formerly Sourcelink.Net)

STATEMENT OF CASH FLOWS

For the quarters ended June 30,2020 and June 30,2019
(unaudited)

Three Months	Three Months
Ended June 30,2020	Ended June 30,2019

CASH FLOWS FROM OPERATING ACTIVITIES

Net Loss	\$	(17,091)	\$	(14,958)
Adjustments to reconcile net Income (loss) to net cash				
Depreciation		277		222
Changes in Operating Assets and Liabilities				
Increase (Decrease) in Accrued Expenses and Accounts Payable		95		0
NET CASH PROVIDED BY (USED) IN OPERATING ACTIVITIES		<u>(16,719)</u>		<u>(14,736)</u>

CASH FLOWS FROM FINANCING ACTIVITIES

Increase (Decrease) in Notes Payable and Loans Payable, Related Parties		5,350		0
Increase (Decrease) in Notes Payable		9,600		9,050
Net Cash provided by (used) in Financing Activities		<u>14,950</u>		<u>9,050</u>

Net Increase (Decrease) in Cash	\$	<u>(1,769)</u>	\$	<u>(5,686)</u>
---------------------------------	----	----------------	----	----------------

Cash at Beginning of Period		1,805		6,708
Cash at End of Period	\$	<u>36</u>	\$	<u>1,022</u>

The accompanying Notes are an integral part of these Financial Statements

The Accompanying Notes are an Integral Part of These Condensed Financial Statements

ONCOLOGY PHARMA, INC.

Notes to Financial Statements for the Quarter Ended June 30, 2020

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Oncology Pharma, Inc., (the “Company”) (formerly SourcingLink.net, Inc.) was incorporated in 1993 and is engaged in the development, manufacturing and commercialization of therapeutics. The Company is a Nevada corporation. The Company has adopted a March 31 Fiscal Year End.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a March 31 year-end.

B. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

D. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

E. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset

deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company follows ASC Topic 740 for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change.

F. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

G. REVENUE RECOGNITION

Revenue will be recognized when persuasive evidence of an arrangement exists, pricing is fixed and determinable, collection is reasonably assured and delivery or performance of service has occurred. Customer prepayments are reflected as deferred revenue as long as there is persuasive evidence that the purchased product will be shipped within a reasonable time. Sales revenue will be recognized upon the completion of provided professional services or the shipment of merchandise to customers.

F. STOCK-BASED COMPENSATION

The Company recognizes share-based compensation, including stock option grants, warrants and restricted stock grants at their fair value on the grant date. Share based payment awards issued to non-employees for services rendered will be recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. Compensation expense is generally recognized on a straight-line basis over the vesting period.

NOTE 2 . RECENT ACCOUNTING PRONOUNCEMENTS

The Company has evaluated the recent accounting pronouncements through June 30, 2020 and believes that none of them will have a material impact on the Company's Financial Statements.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated an accumulated deficit of \$69,987,612 as of June 30, 2020. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company is taking steps to provide the necessary capital to continue its operations. These steps include, but are not limited to: 1) raising equity financing; 2) developing the business model to generate sales.

NOTE 4. CONVERTIBLE NOTES PAYABLE

As of June 30, 2020, the Company the Company was party to Convertible Notes Payable (Exclusive of Convertible Notes Payable to Related Party) of \$135,600 convertible into the common shares of the Company. On March 31, 2020 both of Bright Star International, Inc. and Life Sciences Journeys, Inc. have agreed to forgive all accrued interest due but unpaid on all convertible notes held by Bright Star International, Inc. and Life Sciences Journeys, Inc. as of March 31, 2020 ("Fiscal Year End Notes"). Bright Star International, Inc. and Life Sciences Journeys, Inc. have agreed that no further interest shall accrue on the Fiscal Year End Notes.

Date of Note Issuance	Outstanding Balance (\$)	Holder
4/4/2014	\$ 5,550	Brightstar International, Inc. ("BSI")
11/25/2016	\$ 2,000	BSI
1/20/2017	\$ 2,700	BSI
4/3/2017	\$ 3,000	BSI
4/12/2017	\$ 1,100	BSI
5/5/2017	\$ 30,000	BSI
5/9/2017	\$ 12,000	BSI
9/14/2017	\$ 4,000	BSI
10/30/2017	\$ 3,500	BSI
1/5/2018	\$ 6,000	BSI
1/18/2018	\$ 1,000	BSI
3/5/2018	\$ 3,000	Life Sciences Journeys, Inc. ("LSJ")
3/2/3 2018	\$ 2,500	LSJ
4/20/2018	\$ 3,500	LSJ
5/18/2018	\$ 5,500	LSJ
7/20/2018	\$ 1,500	LSJ
8/6/2018	\$ 1,100	LSJ
8/31/2018	\$ 1,400	LSJ
11/15/2018	\$ 3,250	LSJ
1/1/2019	\$ 3,500	LSJ
1/15/2019	\$ 1,100	LSJ
1/23/2019	\$ 4,200	LSJ
2/8/2019	\$ 1,750	LSJ
3/6/2019	\$ 2,500	LSJ
3/6/2019	\$ 3,500	LSJ
4/6/2019	\$ 3,000	LSJ
6/25/2019	\$ 1,050	LSJ
10/31/2019	\$ 4,300	LSJ
11/1/2019	\$ 1,300	LSJ
12/31/2019	\$ 2,100	LSJ
3/11/2020	\$ 3,500	BSI
3/27/2020	\$ 1,600	LSJ

4/6/2020	\$	600	LSJ
4/14/2020	\$	3,750	LSJ
4/30/2020	\$	2,000	LSJ
5/21/2020	\$	2,000	LSJ
5/29/2020	\$	1,250	LSJ
Total		\$ 135,600	

NOTE 5. RELATED PARTY TRANSACTIONS

As of June, 30 2020 the Company is indebted to related parties in the amount of \$910 (Charles Wagner, Chairman)

On June 30, 2020 the Company issued a convertible note to Charles Wagner, in the principal amount of \$2,500. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On June 30, 2020 the Company issued a convertible note to Charles Wagner, in the principal amount of \$5,350. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

NOTE 6. STOCKHOLDER'S EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as of June 30, 2020:

Preferred Stock, \$0.001 Par Value
100,000,000 Shares Authorized
1 Share Issued

Common Stock, \$0.001 Par Value
900,000,000 Shares Authorized
150,146,092 Shares Issued

NOTE 7. SUBSEQUENT EVENTS.

On July 20, 2020 the Company issued a convertible note to Life Sciences Journeys, Inc. in the principal amount of \$6,000. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On July 28, 2020 the Company issued a convertible note to Life Sciences Journeys, Inc. in the principal amount of \$5,500. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On July 28, 2020 the Company issued a convertible note to Life Sciences Journeys, Inc. in the principal amount of \$2,500. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On August 6, 2020 the Company issued a convertible note to Life Sciences Journeys, Inc. in the principal amount of \$10,000. The Note bears interest at the rate of 6% per annum. Principal and accrued interest is payable at the demand of the holder.

The holder of the note has the right at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest into shares of fully paid and non-assessable shares of the common stock of the Company at a price of \$0.001 per share.

On August 11, 2020, the Company issued 5,000,000 common shares to Kalos Therapeutics Inc. as a License Fee payment.

5) Issuer's Business, Products and Services

Business:

The licensing, development, manufacturing and commercialization of therapeutics. Research is currently conducted by licensors.

Subsidiaries, parents, or affiliated companies:

n/a

Principal products or services, and their markets:

Research, development and commercialization of oncology products designed to provide therapeutics for many types of cancer.

Officers and Directors:

Chairman of the Board of Directors Charles Wagner

Chief Executive Officer George Malasek

Chief Scientific Officer Vijay Mahant, M.S. Ph.D.

Carlos Barnett – Director

Stefan Gruenwald, Ph.D./MD – Director

Shawn Crouse – Director

The address for all Officers and Directors is:
c/o Oncology Pharma, Inc.

One Sansome Street
Ste. 305 PMB # 100517
San Francisco CA 94104

6) Issuer's Facilities

The issuer leases office space at One Sansome Street in San Francisco, California.

7) Officers, Directors, and Control Persons

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Charles Wagner</u>	<u>Chairman/Director</u>	San Francisco CA	60,000,764	<u>Common</u>	<u>38.6%</u>	<u>Restricted</u>
<u>George Malasek</u>	<u>Chief Executive Officer</u>	Carlsbad CA	1,500,020	<u>Common</u>	<u>.97%</u>	<u>Restricted</u>
Carlos Barnett	Director	Carlsbad CA	<u>10,250,000</u> <u>1</u>	<u>Common</u> <u>Preferred</u>	<u>6.66%</u> <u>100%</u>	<u>Restricted</u>
Shawn Crouse	<u>Director</u>	Corte Madera CA	<u>10,350,000</u>	<u>Common</u>	<u>6.67%</u>	<u>Restricted</u>
<u>Vijay Mahant</u>	<u>Chief Scientific Officer</u>	San Diego CA	5,100,000	<u>Common</u>	3.28%	<u>Restricted</u>
<u>Stefan Gruenwald.</u>	<u>Director</u>	Encinitas CA	<u>8,600,000</u>	Common	5.5%	Restricted

8) Legal/Disciplinary History

A)

None of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

B)

There is not any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject.

9) Third Party Providers

Securities Counsel:

Name: Dimitrios Theofilopoulos

Theo Law Firm

4225 Executive Square, Ste. 600

La Jolla, CA 92037

(213)359 3179

dimitri@theolawfirm.com

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, George Malasek certify that:

1. I have reviewed this Quarterly Disclosure Statement of Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

9/4/2020 [Date]

/s/George Malasek [George Malasek]

Principal Financial Officer:

I, Charles Wagner certify that:

1. I have reviewed this Quarterly Disclosure Statement of Oncology Pharma, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

9/4/2020 [Date]

/s/Charles Wagner [Charles Wagner]